Catalyst Pharmaceuticals (NASDAQ:CPRX) specializes in developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. With a primary focus on addressing unmet medical needs, their notable product, Firdapse, is a treatment designed to improve muscle strength in patients suffering from Lambert-Eaton myasthenic syndrome (LEMS). The company is committed to expanding its product portfolio through rigorous research and development initiatives, aiming to enhance the quality of life for patients dealing with severe diseases. Catalyst Pharmaceuticals is continually working on bringing new solutions to the market and supporting the communities they serve through patient-centric programs and advocacy.